SPECT/CT Quantification for Theranostics
More power than ever to personalize care.
With more than 1,150 publications referencing theranostics in 20171, there is clear momentum in this fast-growing area of medicine. Combining diagnostics and therapy brings new opportunities for delivering the right treatment at the right time to each patient. But having reliable patient-specific data is essential for achieving this. Traditional SPECT/CT quantification, while promising, is unfortunately cumbersome and inexact—thus rarely used.
The world’s most robust2 SPECT/CT quantification
Automated, precise, and reproducible to within 5%2, xSPECT Quant™ provides the degree of standardized SPECT/CT quantification needed for theranostics and radionuclide therapy. Unrivaled in its level of accuracy3, xSPECT Quant lays the foundation for optimal therapy planning and management.
Specifically designed for 177Lu-based theranostic applications, xSPECT Quant makes it possible to routinely measure early disease response and pinpoint dose activity concentration. Thus helping you better treat and monitor each patient.
What experts say
Ken Herrmann, MD
Chair, Department of Nuclear Medicine
Universitätsklinikum Essen, Germany
“As a guest editor for The Journal of Nuclear Medicine, I had the chance to create a dedicated issue on theranostics. Bringing together and sharing our knowledge will only help propel its use. In my opinion, this is nuclear medicine‘s most exciting development since the introduction of PET and PET/CT.”
The Journal of Nuclear Medicine: Theranostics Supplement (2017)
A collection of 15 articles highlighting the experiences and impressions of researchers and clinicians working in the field.
Insight into theranostics
Case 1 – Metastatic Neuroendocrine Tumor
- 49-year-old male
- Metastatic neuroendocrine tumor with extensive liver involvement
- Underwent peptide receptor radionuclide therapy (PRRT) with 7.5 GBq of 177Lu DOTATATE
Case 2 – Three-time-point study post-therapy
- 70-year-old female
- Liver metastases from neuroendocrine tumor
- Underwent peptide receptor radionuclide therapy (PRRT) with 6.3 GBq of 177Lu DOTATATE
Case 3 – Single-time-point study
- 49-year-old patient
- Advanced pancreatic neuroendocrine tumor
- Initial staging cT4 cNx cM1(HEP) was referred for a fourth cycle of peptide receptor radionuclide therapy (PRRT) with 4.1 GBq 177Lu-somatostatin-receptor (SSTR)-targeting ligand
Data courtesy of Peter Bartenstein
Ludwig Maximillians University
Data courtesy of Dale L. Bailey PhD, Kathy P. Willowson PhD, and
Paul J. Roach MB BS FRACP
Department of Nuclear Medicine
Royal North Shore Hospital & University of Sydney
Written by A. Hans Vija, PhD, Carl von Gall, MD, and Partha Ghosh, MD
Siemens Healthineers Molecular Imaging
1Results of pubmed.gov search for “Theranostics” or “Theragnostics” accessed January 10, 2018. Data on file.
2Accuracy of Bq/ml quantification in reference to NIST, measured using NEMA NU2-94 Test Phantom.
3Based on competitive literature available at time of publication. Data on file.
4Nuclear Medicine/Radiopharmaceuticals Report, Global Forecasts to 2020, Markets and Markets, 2015.
xSPECT Quant is not commercially available in some countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.